Paper36077433
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.
Mossenta M and 4 others. Int J Mol Sci, 2022. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. Papers, record 36077433. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36077433
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Drug Resistance | |
| Glypicans | |
| Humans | |
| Nanotechnology | |
| Therapies, Investigational |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| NA | Governo Italiano | PubMed |
Source PubMed
References189
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35785307 | Research on the Construction of Bispecific-Targeted Sustained-Release Drug-Delivery Microspheres and Their Function in Treatment of Hepatocellular Carcinoma. | ACS Omega | 2022 | https://conductscience.org/library/papers/35785307 | PubMed |
| 2 | 29719757 | Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. | Beilstein J Nanotechnol | 2018 | https://conductscience.org/library/papers/29719757 | PubMed |
| 3 | 31953246 | Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. | Cancer Immunol Res | 2020 | https://conductscience.org/library/papers/31953246 | PubMed |
| 4 | 18505598 | Glypicans. | Genome Biol | 2008 | https://conductscience.org/library/papers/18505598 | PubMed |
| 5 | 31116141 | Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma. | Clin Transl Gastroenterol | 2019 | https://conductscience.org/library/papers/31116141 | PubMed |
| 6 | 31056726 | Epigenetics of hepatocellular carcinoma. | Clin Transl Med | 2019 | https://conductscience.org/library/papers/31056726 | PubMed |
| 7 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 8 | 18480006 | Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. | Am J Clin Pathol | 2008 | https://conductscience.org/library/papers/18480006 | PubMed |
| 9 | 29162156 | The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. | Eur J Med Res | 2017 | https://conductscience.org/library/papers/29162156 | PubMed |
| 10 | 30665869 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30665869 | PubMed |
| 11 | 31954487 | Advances in molecular classification and precision oncology in hepatocellular carcinoma. | J Hepatol | 2020 | https://conductscience.org/library/papers/31954487 | PubMed |
| 12 | 27074018 | Modeling of Hepatocytes Proliferation Isolated from Proximal and Distal Zones from Human Hepatocellular Carcinoma Lesion. | PLoS One | 2016 | https://conductscience.org/library/papers/27074018 | PubMed |
| 13 | 31841768 | Towards the overcoming of anticancer drug resistance mediated by p53 mutations. | Drug Resist Updat | 2020 | https://conductscience.org/library/papers/31841768 | PubMed |
| 14 | 11084048 | Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. | J Biol Chem | 2001 | https://conductscience.org/library/papers/11084048 | PubMed |
| 15 | 26341193 | Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. | Drug Resist Updat | 2015 | https://conductscience.org/library/papers/26341193 | PubMed |
| 16 | 30061739 | Molecular therapies and precision medicine for hepatocellular carcinoma. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/30061739 | PubMed |
| 17 | 29568237 | Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. | Cancer Cell Int | 2018 | https://conductscience.org/library/papers/29568237 | PubMed |
| 18 | 25457975 | The folate receptor as a rational therapeutic target for personalized cancer treatment. | Drug Resist Updat | 2014 | https://conductscience.org/library/papers/25457975 | PubMed |
| 19 | 34866166 | Nanoparticles for Cancer Therapy: Current Progress and Challenges. | Nanoscale Res Lett | 2021 | https://conductscience.org/library/papers/34866166 | PubMed |
| 20 | 32127929 | Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. | J Cancer | 2020 | https://conductscience.org/library/papers/32127929 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42182336 | Ablation of glypican-3 enhances radiosensitivity in liver cancer by prolonging G2/M arrest and activating the ATM/CHK2 pathway. | bioRxiv | 2026 | https://conductscience.org/library/papers/42182336 | PubMed |
| 41675547 | Emerging nanomedicine strategies for hepatocellular carcinoma therapy. | IMetaOmics | 2024 | https://conductscience.org/library/papers/41675547 | PubMed |
| 40722645 | Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights. | Biomedicines | 2025 | https://conductscience.org/library/papers/40722645 | PubMed |
| 39660335 | Alpha-fetoprotein, glypican-3, and kininogen-1 as biomarkers for the diagnosis of hepatocellular carcinoma. | Int J Clin Exp Pathol | 2024 | https://conductscience.org/library/papers/39660335 | PubMed |
| 39011387 | Ultrasound-Responsive Nanodelivery System of GPC3-Targeting and Sonosensitizer for Visualized Hepatocellular Carcinoma Therapy. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/39011387 | PubMed |
| 38882543 | Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/38882543 | PubMed |
| 38213137 | Study on the Mechanism of Notch Pathway Mediates the Role of Lenvatinib-resistant Hepatocellular Carcinoma Based on Organoids. | Curr Mol Med | 2025 | https://conductscience.org/library/papers/38213137 | PubMed |
| 37240286 | Advances in Immunotherapy and Innovative Therapeutic Approaches for Cancer Treatment: Editorial to the Special Issue "State-of-the-Art Molecular Oncology in Italy". | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37240286 | PubMed |
| 36559264 | Co-Delivery System of Curcumin and Colchicine Using Functionalized Mesoporous Silica Nanoparticles Promotes Anticancer and Apoptosis Effects. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36559264 | PubMed |
| 36499616 | Activated Hepatic Stellate Cells in Hepatocellular Carcinoma: Their Role as a Potential Target for Future Therapies. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36499616 | PubMed |
Genes55
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36077433
GET https://conductscience.org/api/papers/v1/36077433/references?page=2